Literature DB >> 526917

Ocular assessment of patients treated with tamoxifen.

M Beck, P V Mills.   

Abstract

Tamoxifen is a specific estrogen antagonist used in the treatment of breast cancer. In a previous study, corneal and retinal changes were reported in four patients receiving high-dose tamoxifen therapy for greater than 1 year. Nineteen patients treated with tamoxifen for periods of 3 months to 4 years at normal dose levels have been studied and no ocular changes attributable to the drug were observed.

Entities:  

Mesh：

Substances：

Year:  1979        PMID： 526917

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN： 0361-5960


  7 in total

Review 1.  Systemic adjuvant therapy for node-negative breast cancer.

Authors:  A D Ginsburg; D J Perrault; K I Pritchard; G P Browman; P B McCulloch; J Skillings
Journal:  CMAJ       Date:  1989-09-01       Impact factor: 8.262

Review 2.  Tamoxifen. A reappraisal of its pharmacodynamic and pharmacokinetic properties, and therapeutic use.

Authors:  M M Buckley; K L Goa
Journal:  Drugs       Date:  1989-04       Impact factor: 9.546

3.  Retinal function in patients treated with tamoxifen.

Authors:  Sung Eun Song Watanabe; Adriana Berezovsky; Márcia Motono; Paula Yuri Sacai; Josenilson Martins Pereira; Juliana Maria Ferraz Sallum; Luiz Henrique Gebrim; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2010-04       Impact factor: 2.379

Review 4.  Fourteenth Gaddum Memorial Lecture. A current view of tamoxifen for the treatment and prevention of breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  1993-10       Impact factor: 8.739

Review 5.  Clinically important ocular reactions to systemic drug therapy.

Authors:  I G Rennie
Journal:  Drug Saf       Date:  1993-09       Impact factor: 5.606

Review 6.  A risk-benefit assessment of tamoxifen therapy.

Authors:  W H Catherino; V C Jordan
Journal:  Drug Saf       Date:  1993-05       Impact factor: 5.606

7.  Long-term tamoxifen adjuvant therapy in node-positive breast cancer: a metabolic and pilot clinical study.

Authors:  D C Tormey; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1984       Impact factor: 4.872
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.